BIVI - BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman | Benzinga

SAN FRANCISCO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ:BIVI) investors who suffered substantial losses to submit your losses now.

Class Period: Aug. 5, 2021 – Nov. 29, 2023
Lead Plaintiff Deadline: Mar. 19, 2024
Visit: www.hbsslaw.com/investor-fraud/BIVI
Contact An Attorney Now: BIVI@hbsslaw.com
                                                   844-916-0895

BioVie Inc. (BIVI) Securities Class Action:

The litigation focuses on the propriety of BioVie's disclosures concerning its adherence to Good Clinical Practice ("GCP") and protocols related to its Phase 3 clinical trial of NE3107, a potential Alzheimer's disease drug.

On Aug. 5, 2021, BioVie announced that it enrolled the first patient in its Phase 3 clinical trial of NE3107 and thereafter assured investors that the "[t]rial continues to have a good safety profile and low discontinuation rate." On Sep. 26, 2023, BioVie announced completion of the last treatment visit in the trial and investors eagerly awaited the results for a drug, which the company touted as having a "10+ billion annual peak sales potential."

The complaint alleges BioVie made misleading statements and concealed that: (1) BioVie was not ...

BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman>Full story available on Benzinga.com